Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 21 - Aug 26
Effect of subcutaneous Tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial
Compounded Tirzepatide Compounded Semaglutide Same active ingredient as Ozempic & Wegovy GLP-1 receptor agonist (single target) Average weight loss: ~15% of body weight Once-weekly subcutaneous injection Gradual dose titration over 48 weeks Well-studied safety profile Good starting option for most patients Compounded Tirzepatide Same active ingredient as Mounjaro & Zepbound Dual GLP-1 + GIP receptor agonist Average weight loss: up to 21% of body weight Once-weekly subcutaneous injection Gradual dose titration over 48 weeks Additional blood sugar regulation via GIP pathway May be more effective for patients with insulin resistance Not sure which is right for you
Super fast delivery everytime
S., Younis, N
Clinical studies confirm that chronic treatment with AOD9604 showed no adverse effect on insulin sensitivity, making it a metabolically selective approach to body composition optimization under medical supervision
